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Background and Purpose—A full appreciation of the presence of cerebral vascular lesions in cognitively impaired patients
can be ultimately reached at the neuropathological level. However, there are no detailed guidelines regarding what
neuropathologists should look for at autopsy in cases of suspected vascular dementia or vascular cognitive impairment.
We aimed at surveying the postmortem neuropathological procedures used in different centers in examining brain
lesions of presumable or possible vascular origin in cognitively impaired patients.
Methods—Thirteen laboratories participated in the survey by filling in a semistructured questionnaire. We reviewed
sampling and histology procedures in use and the neuropathological definitions of some of these lesions. Neuropatho-
logical criteria for the definition of a vascular origin of the dementing process were also surveyed.
Results—A large variability across centers was observed in the procedures used for the neuropathological examination and
the histology techniques. Heterogeneity existed also in the definition of commonly found lesions (eg, white matter
alterations, small vessel disease), interpretation of whether or not the lesions were reputed to be of vascular origin, and
consequently in the interpretation of the cause of cognitive decline.
Conclusions—The appreciation of the presence of neuropathologically verified vascular lesions in cognitively impaired
cases may be heavily influenced by the laboratory tools used and also by the heterogeneity of the criteria applied in
different centers. Harmonization of neuropathological procedures is badly needed in the field of vascular dementia and
vascular cognitive impairment to better understand the association between various vascular lesions and clinical symptoms
such as cognitive impairment. (Stroke. 2006;37:1005-1009.)
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Dementia is a major health problem in developed coun-tries. It is generally thought that therapeutic and preven-
tive approaches may vary according to different dementia
subtypes, and typically, the cases of dementia are divided
according to the underlying cause. However, establishing the
main etiology in some cases of dementia is difficult. The
general belief that the characterization of the causes of
dementia can be definitively reached on pathological grounds
is also echoed in current diagnostic criteria.1,2 Concerning
vascular dementia (VaD), 1 of the 2 main types of dementia,
the diagnosis is reached when the most relevant brain lesions
are considered to be of vascular origin. Despite this, the
definition of vascular lesions does not always appear straight-
forward,3 and the characterization of pathological lesions
associated with vascular cognitive decline is a major current
problem with important reflections for clinical practice and
interpretation of epidemiological data.4,5 A similar problem
also affects the field of neurodegenerative dementias in which
vascular lesions are frequently associated.6,7 These difficul-
ties are reflected in the difference found in pathological series
of demented patients in terms of frequency of VaD cases;8
these discrepancies might partly be explained by the hetero-
geneity in the pathological examination procedures used in
different centers.
Although there is a general agreement that some types of
vascular lesions may cause cognitive deterioration,8–10 it
seems crucial to reach a consensus on what is meant under the
definition of “vascular.” Moreover, it appears of interest to
examine what is currently performed in neuropathology
laboratories because harmonization is of the utmost impor-
tance for future work in the field. Standardization approaches
have been previously undertaken in the field of Alzheimer
disease11 and should also be proposed for VaD.
With these considerations in mind, we aimed at surveying
the procedures used in different centers in examining from
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the neuropathological point of view cases of possible VaD or
vascular cognitive impairment. In particular, we surveyed
brain sampling and histology techniques, pathological defi-
nitions of some lesions of possible vascular origin, and
criteria applied for the final interpretation of autopsy finding
in terms of the cause of cognitive impairment.
Methods
To collect all the supposedly needed information about the proce-
dures used in different centers, a semistructured questionnaire was
developed by consensus among 4 neuropathologists and 1 neurolo-
gist who had undergone neuropathological training. The form con-
tained questions about the following areas: (1) general pathological
procedures such as brain cutting, sampling, and staining; (2) paren-
chyma alterations assessment (type and definition criteria of each
lesion); (3) vessel diseases (definition, sampling region, quantitative
assessment); and (4) general issues such as interpretation of findings
and definition of the appreciation of the role of vascular lesions in
relation to the cognitive status and to other possible coexistent
pathological diseases. Most of the questions allowed multiple an-
swers. The form in its final version was then circulated among 13
centers selected on the basis of their recognized expertise in the
pathological examination of cases of dementia or more specifically
of VaD and their willingness to participate. Some of the centers were
selected on the basis of ongoing collaborative studies and networks
in the field of cognitive impairment.12 No other specific criteria were
followed to select the centers participating in the study. Six centers
declined to participate because of a lack of interest in the topic or
they never responded to the invitation.
Results
General Neuropathological Procedures (Table 1)
The vessels of the circle of Willis are examined in all the
centers, and the majority of centers also examine the carotid
arteries, the heart, and the kidneys (if no restrictions are
imposed in the autopsy consent); however, only a minority
examines the vertebral arteries. Most of the centers perform
cutting of the entire brain (left and right hemisphere), whereas
a few examine only 1 hemisphere, usually because the
remaining is frozen. The brain is cut in the coronal plane in all
centers; no one uses sagittal sectioning. Interestingly, trans-
verse cutting (ie, the slice plane used in computed tomogra-
phy and magnetic resonance scans) is performed in only 1
center. In most of the centers, sampling for microscopic
evaluation is done in many cerebral areas. Staining of the
entire coronal sections is used in 5 centers; specific stains for
myelin are used quite consistently across centers.
Parenchyma Changes Assessment
Lesions are examined in the formalin-fixed brain in 8 centers
and in stained coronal sections in the remaining 5 centers.
Considering the question about which lesions among those
listed in the questionnaire are considered vascular (Table 2),
some lesions such as large and small infarcts are clearly and
consistently across centers classified as vascular. For the
etiological classification of other lesion types, discrepancies
exist. For example, only about one third of centers attribute to
white matter rarefaction of any degree a vascular signifi-
cance. Also, when considering severe white matter rarefac-
tion, only 6 of 13 centers consider it vascular. Other lesion
types that were inconsistently considered vascular were
cortical granular atrophy, laminar necrosis, and incomplete
infarcts. Hippocampal sclerosis was defined as vascular in
only 4 centers and enlarged perivascular spaces in 8. None of
the centers considered the enlargement of lateral ventricles to
represent a vascular lesion. However, even considering le-
sions that are consistently reported to be recognized as
vascular, discrepancies exist. For example, a consensus does
not exist in terms of definition of lacunar infarct (Table 3),
and only 9 centers make a distinction between lacunes and
TABLE 1. General Pathological Procedures, Sampling, and
Histology Techniques (survey questions are also reported#)
n* (%)
Examination of large vessels and other organs (On a routine basis, do
you examine?)
Carotid arteries in the neck 9 (69.2)
Vertebral arteries 2 (15.4)
Willis circle vessels 13 (100)
Heart 9 (69.2)
Kidney 10 (76.9)
Sampling and brain cutting (Where do you sample, and how do you cut
the brain?)
Sampling from only half of the brain 5 (38.4)
Coronal cutting 13 (100)
Transverse cutting (in addition to coronal) 1 (7.7)
Sagittal cutting 0 (0)
Site of sampling for microscopic examination (Where do you sample for
microscopic examination?)
Middle frontal gyrus 12 (92.3)
Superior and middle temporal gyri 11 (84.6)
Inferior parietal lobule 10 (76.9)
Occipital cortex 12 (92.3)
Hippocampus with entorhinal cortex 12 (92.3)
White matter 12 (92.3)





Medulla oblongata 10 (76.9)
Basal structures 11 (84.6)
Any lesion seen macroscopically 12 (92.3)
Histology assessment: staining (Which of the following brain parts do
you stain?)
Coronal brain sections 13 (23.1)
Whole hemibrain 1 (7.7)
Entire lobes 2 (15.4)
Small blocks only 10 (76.9)
Histology assessment: staining (Which of the following stains do
you apply?)
Staining for myelin 11 (84.6)
Staining for nerve fibers 7 (53.8)
Silver staining 9 (69.2)
Staining for astroglial cells 7 (53.8)
*No. of centers performing that specific examination; #multiple answers allowed.
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microinfarcts. Concerning infarcts, their volume is assessed
only by about half of the surveyed centers, and only 5 centers
declare to assess incomplete gray matter infarction (Table 3).
The definition of this latter type of lesion clearly represents an
open issue; when we asked to report the definition, we
obtained different answers. In some centers, incomplete
infarction was defined as the presence of loss of neurons
without obvious other tissue loss. In other centers, this term
was used only for white matter changes characterized by
myelin pallor; finally, some reserved the term incomplete
infarction to describe laminar necrosis of the cortex. Other
neuropathologists stated that they do not use the term or even
that they do not exactly know what it means. Similarly, the
definition of white matter rarefaction follows different crite-
ria (Table 4), whereas a quantitative assessment of white
matter changes is performed in only 4 of 13 centers. Finally,
the presence of Wallerian degeneration is recorded in 7 of 13
centers, that of gliosis of the white matter by 10 centers, and
of the gray matter by 11 centers, although its quantification is
performed in only 5 centers.
Small Vessel Assessment (Table 5)
Of interest, heterogeneity exists across centers even in the
definition of a small vessel. Some centers identify small
vessel on the basis of diameter size, whereas others identify
small vessel on the basis of location (eg, in subcortical areas).
This notwithstanding, all except 1 center reported to perform
TABLE 2. Lesions Considered of Vascular Origin by Surveyed
Neuropathologists (recorded answers to the question “Which of
these lesions do you consider vascular?”)
n* (%)
Cerebral infarcts 13 (100)
Lacunar infarcts 13 (100)
Cortical microinfarctsamyloid angiopathy 11 (84.6)
Multiple large infarctsamyloid angiopathy 10 (76.9)
Enlarged perivascular space 8 (61.5)
White matter rarefaction (any degree) 4 (30.8)
Severe white matter rarefaction 6 (46.1)
Ventricular enlargement 0 (0)
Hippocampal sclerosis 4 (30.8)
Cortical granular atrophy 6 (46.1)
Laminar necrosis of the cortex 9 (69.2)
Incomplete infarcts 7 (53.8)
*No. of centers performing that specific examination.
TABLE 3. Definition of Lacunar Infarct According to Diameter,
Volume, or Location and Assessment of Brain Infarcts (survey
questions are also reported§)
n* (%)
Definition of lacunar infarct (Which of the following define a lacunar infarct
in your practice?)
Any infarct with diameter 15 mm 3 (23.1)
Any infarct with diameter 15 mm and typical site# 10 (76.9)
Any infarct with diameter 15 mm associated with
arteriolosclerosis
3 (23.1)
Any infarct with volume 1.0 mL 1 (7.7)
Assessment of brain infarcts (For brain infarcts, do you record or search?)
Bilateral occurrence 13 (100)
Location 13 (100)
Total lesion volume 7 (53.8)
Multiplicity 12 (92.3)
Presence of incomplete grey matter infarcts 5 (38.5)
*No. of centers performing that specific examination; #basal ganglia,
thalamus, pons, hemispheric white matter; §multiple answers allowed.
TABLE 4. Definitions Used for White Matter Rarefaction in
Different Centers (recorded answer to the question “How do
you define the rarefaction of white matter?”#)
n* (%)
Appearance paler than normal 7 (53.8)
Loose appearance of myelinated fibers 8 (61.5)
Oligodendrocyte no. reduction 3 (23.1)
Axonal loss 6 (46.1)
Presence of gliosis 8 (61.5)
Combination of the above 3 (23.1)
*No. of centers performing that specific examination; #multiple answers allowed.
TABLE 5. Small Vessel Disease Assessment (survey questions
are also reported#)
n* (%)
Definition of small vessels (What do you mean for small vessels?)
All vessels with diameter 500 m 6 (46.1)
Only arterioles 1 (7.7)
All vessels deeper than cortex 6 (46.1)
All vessels with diameter 50 m 1 (7.7)
All the vessels within the brain parenchymaall vessels
with a diameter 500 m in the leptomeningeal space
1 (7.7)
Sites of small vessels examination (In what cerebral region do you examine
small vessels?)
Cortex 10 (76.9)
White matter 12 (92.3)
Basal ganglia 11 (84.6)
Thalamus 10 (76.9)
Brainstem 8 (61.5)
Staining of small vessels (What staining do you apply to examine
small vessels?)
Hematoxylin and eosin 11 (84.6)
Masson’s trichrome 2 (15.4)
Van Gieson’s elastica 4 (30.8)
Other 4 (30.8)
Alterations reputed as hallmarks of small vessel disease (What do you
define as small vessel disease?)
Hyaline degeneration of tunica media 11 (84.6)
Loss of smooth muscle cells in tunica media 3 (23.1)
Thickening of vessel walllumen narrowing 12 (92.3)
Lypohyalinosis 10 (76.9)
Necrotic aspects in the vessel wall 9 (69.2)
*No. of centers performing that specific examination; #multiple answers allowed.
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routine evaluation of small vessels. Brain areas for small
vessels examination are also different to some extent.
Hematoxylin-eosin is the staining of choice for small vessels
evaluation in most centers, whereas more specific stains are
seldom used. None of the centers assess the density of small
vessel per unit area. Considering histological aspects of small
vessel disease, some findings such as hyaline degeneration of
tunica media, vessel wall thickening and lumen narrowing,
lypohyalinosis, and necrosis of the wall are rather consis-
tently recognized as hallmarks of small vessels disease,
whereas the isolated loss of smooth muscle cells is not
considered as such by all the investigators.
Cerebral Amyloid Angiopathy (Table 6)
Assessment of cerebral amyloid angiopathy (CAA) is specif-
ically performed in all autopsy cases in 8 of the 13 inter-
viewed centers. In the remaining ones, CAA is assessed only
for specific reasons such as the presence of cognitive decline
or suggestion by routine histological assessment. However,
the staining methods for assessing CAA were rather different
across centers. Surprisingly, none of the centers use thioflavine
S, a method strongly suggested by the Consortium to Establish
a Registry for Alzheimer’s Disease (CERAD) group.13 Quanti-
fication of CAA is performed in 10 of 13 centers.
Interpretation of Findings
The questions for this part were left open and were mainly
aimed at exploring how pathologists summarize and interpret
the presence of vascular lesions in relation to the occurrence
of cognitive decline. In response to the question of when a
patient is considered to have vascular alterations in the brain,
5 of the 13 centers indicated that this statement appears in
their final report when a certain subjective threshold of the
above-discussed lesions is surpassed. In the remaining cen-
ters, the presence of any amount of vascular changes is
considered sufficient. In 1 center, a patient is defined as
having vascular lesions when severe gross atherosclerosis of
the circle of Willis or substantial infarct or CAA associated
with microinfarcts are found; in another, when the vascular
lesions are considered more severe than minimal; and in 1
center, when a territorial infarct or multiple lacunes or small
vessel disease are found. In 2 centers, the requirement for
defining a demented patient as having vascular lesions is that
these latter are in the parenchyma (ie, lesions of the vessels
are not considered).
We then asked when a patient is considered to have
exclusively vascular lesions. Also in this case, the answers
were rather sparse, and sometimes the pathologists reported
to be uncomfortable with this statement. In some centers, the
criterion is mostly based on the absence of evidence of other
types of lesions, but the following answers were also re-
ported: presence of vascular lesions in associative areas;
presence of infarcts in the absence of Alzheimer disease
pathology; exclusion of substantial degenerative pathology
by silver or immunostaining (1 center each); and 1 patholo-
gist declared that a patient is never defined as having solely
vascular pathology in his center.
The last question aimed at assessing criteria for defining
under neuropathological examination a cognitively impaired
patient to have primarily vascular lesions. The following
findings were reported by the various services to reflect this
condition: (1) accompanying changes not sufficient to cause
dementia; (2) accompanying lesions of the Alzheimer or
Lewy body type of mild degree; (3) large multiple left
hemispheric infarcts or angular gyrus infarcts or multiple
lacunes in the putamen, caudate, or thalamus or multiple
microinfarcts in the cortex, basal ganglia, and thalamus; (4)
multiple infarcts and only mild Alzheimer-type changes; (5)
severe vascular lesions and minimal lesions of other types;
(6) volume of vascular lesions 30 mL; (7) predominant
vascular lesion in associative areas; (8) substantial vascular
pathology and absence of Alzheimer disease changes; and (9)
severity of senile changes not exceeding those reputed as age
related. The pathologist of 1 center stated that this definition is
impossible to be reached solely on neuropathological grounds
and requires additional clinical and neuroimaging data.
Discussion
We performed an explorative survey aimed at gathering data
about neuropathological procedures used in different centers
in assessing cases of dementia with a focus on vascular
pathology; to the best of our knowledge, for the first time, an
overview of these procedures is provided. The most relevant
result of the survey is the finding of a significant heteroge-
neity across centers in the pathological procedures for assess-
ing lesions with possible or even definite vascular origin and,
surprisingly, also in the consideration of what lesions are
considered expression of a vascular process. The examination
of the results of the survey also suggests that, at present, the
assumption contained in some diagnostic criteria sets1,2 that
pathology may provide final demonstration of a vascular
etiology of dementing syndromes is likely to be biased by a
number of methodological limitations besides the fact that
pathological diagnostic criteria do not exist. In this regard, it
is to be noted that our study was not aimed at developing or
proposing new criteria for the pathological diagnosis of VaD
because this was felt premature considering the present status
of knowledge of the topic and that even clear definitions for
many lesion types are still lacking. In this sense, it seems
TABLE 6. CAA Assessment (survey questions are also reported)
n* (%)
Assessment (When do you search for amyloid angiopathy on a
routine basis?)
In all autopsy cases 8 (61.5)
Only in patients with cognitive decline 1 (7.7)
If suggested by hematoxylin and eosin 4 (30.8)
Histological methods (What histological methods do you use
to assess amyloid angiopathy?)#
Only hematoxylin and eosin 0 (0)
Only Congo red 3 (23.1)
Thioflavine S 0 (0)
Only -amyloid antibodies 4 (30.8)
Congo red-amyloid antibodies 6 (46.1)
-amyloid antibodiessilver impregnation 1 (7.7)
*No. of centers performing that specific examination; #multiple answers allowed.
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advisable that future guidelines be issued not only to better
define the type of lesions to be searched for in cases of VaD
or vascular cognitive impairment but also to define the
technical procedures for that purpose. In the meantime,
abandonment of terms such as “lacune,” which are the source
of confusion in the field and a careful description of brain
lesions in terms of morphology, size, number, and site, could
allow at least the comparison between different studies.
Overall, the present survey shows that neuropathological
procedures are heterogeneous and that different neuropatho-
logical services apply different definition and criteria even for
lesions such as infarcts and small vessels disease that are
considered to be among the hallmarks of vascular cognitive
impairment. Moreover, the study of some lesions is not
customarily performed by all the centers. Finally, the inter-
pretation of findings is subjected to major interindividual
variability. At present, it seems reasonable to conclude that
the appreciation of the contribution of pathologically detected
vascular lesions to cognitive impairment is likely to be
heavily influenced by researchers’ methods and beliefs.
A limitation of this study was in the choice of the
participating centers that did not follow any specifically
structured protocol and, therefore, might have been biased by
several factors. This notwithstanding, we believe that the
expertise of the involved centers provides sufficient support
for the argument that such a variability in fact exists in the
assessment and interpretation of brain vascular lesions. It
might be supposed that the heterogeneity could be even
higher should centers with less expertise be involved in the
survey.
In conclusion, a large variability in the pathological assess-
ment of lesions of possible vascular origin has been shown by
this survey. A consensus agreement of the procedures to be
followed and criteria for evaluation of lesions similar to those
existing for Alzheimer disease11,13,14 and dementia with Lewy
bodies15 is urgently needed.
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Genomic Medicine, University of Sheffield, Sheffield, UK); Kurt
Jellinger (Institute of Clinical Neurobiology, Vienna, Austria);
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ical Center, Amsterdam, The Netherlands); Ga´bor G. Kova´cs (Na-
tional Institute of Psychiatry and Neurology, Budapest); David
Munoz (St. Michael’s Hospital, University of Toronto, Canada); Jun
Ogata (Department of Pathology, National Cardiovascular Center,
Osaka, Japan); Anders Paetau (Department of Pathology, University
of Helsinki, Finland); Jose´ Pimentel (Laboratory of Neuropathology,
Institute of Molecular Medicine, Hospital de Santa Maria, Lisboa,
Portugal); Tuomo Polvikoski (Institute for Ageing and Health,
Newcastle General Hospital, Newcastle-on-Tyne, UK); Edward
Stopa (Department of Neuropathology, Brown Medical School,
Rhode Island Hospital, Providence, RI); Lon White (Pacific Health
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